Don’t miss your chance to interact with Life Sciences industry key players over the course of this 2-day virtual event. Use this code to save an extra 10% off: D10-999-IPW20. Register now!
Visit: https://www.americanconference.com/biosimilars/ or call 888-224-2480
The Future of Biosimilars Hangs in the Balance.
The Supreme Court will decide whether the ACA’s individual mandate is constitutional. Several pieces of legislation related to biosimilars remain pending, the development pipeline is clogged by patent litigation roadblocks, and stakeholders are now seeking to carve a path forward as they battle myriad of challenges posed by the global pandemic.
Amid these newfound risk factors and uncertainty, you simply can’t afford to miss your chance to join government, in-house decision makers and leading industry thought leaders at ACI’s 11th Summit on Biosimilars & Innovator Biologics, in a fully interactive virtual format.
Here are some top reasons why you should attend:
EXCLUSIVE INSIGHTS FROM:
Markus H. Meier
Assistant Director, Health Care Division Bureau of Competition
U.S. Federal Trade Commission
Acting Director, Policy Staff
Office of Therapeutic Biologics and Biosimilars
Office of New Drugs, Center for Drug Evaluation and Research
U.S. Food & Drug Administration
ASSOCIATION INSIGHTS FROM:
• Association for Accessible Medicines (AAM)
• Biotechnology Innovation Organization (BIO
• Pharmaceutical Research and Manufacturers of America (PhRMA)
INDUSTRY ACUMEN FROM:
• Amgen Inc.
• Apotex Inc.
• Baxter Healthcare Corporation
• Biocon Biologics
• Eisai Inc.
• Fosun Pharma USA
• Fresenius Kabi
• 2 Days of learning for one great price of $1595 if you register by September 4th
Register today or call 888-224-2480. Use this code to save an extra 10% off: D10-999-IPW20